Content
12/01/2023
Boston, MA USA
Allotex
completed $30 million Series B Round funding. Investors include
Exor Ventures, Junson Capital, KCK MedTech, Panakes Partners, Supernova Invest.
About
Allotex Inc. is a pioneering biologics and device company focused on developing innovative therapeutic solutions for vision correction. By utilizing precisely shaped human corneal allografts, Allotex creates a natural, removable inlay, offering patients a safe, permanent vision correction option. With a commitment to advancing vision correction, Allotex is dedicated to improving the lives of individuals affected by presbyopia and other refractive disorders of the human eye.
Startup
Sector:
MedTech
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
